Namwiwat Medical vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Namwiwat Medical (NAM.BK)

Q3 202621 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

August 202621 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

Latest21 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest25 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.